Helsinn and Pfizer Laboratories (Pty) Ltd Sign a License Agreement for the Marketing of Aloxi(R) in South Africa.
PR Newswire Europe, March, 2006
LUGANO, Switzerland and JOHANNESBURG, South Africa, March 10 /PRNewswire/ -- Helsinn Healthcare SA, and Pfizer Laboratories (Pty) Ltd, announce the signing of an agreement granting Pfizer in South Africa, the exclusive license and distribution rights of Aloxi(R) (Palonosetron hydrochloride), a therapy for the prevention of nausea and vomiting induced by chemotherapy. Aloxi(R) will be launched in South Africa under the trade name Onicit(R).
Aloxi(R) is a potent and long-lasting antiemetic belonging to the second generation of serotonin (5-HT3) antagonists, the leading class for the prevention of nausea and vomiting induced by chemotherapy. Aloxi(R) showed a great efficacy during the acute and delayed phase after chemotherapy treatment as compared to other...
Most Recent Business Articles
- Multiple criteria evaluation and optimization of transportation systems
- Multi-criteria analysis procedure for sustainable mobility evaluation in urban areas
- A two-leveled multi-objective symbiotic evolutionary algorithm for the hub and spoke location problem
- Multi-criteria analysis for evaluating the impacts of intelligent speed adaptation
- The development of Taiwan arterial traffic-adaptive signal control system and its field test: a Taiwan experience
Most Recent Business Publications
Most Popular Business Articles
- 7 tips for effective listening: productive listening does not occur naturally. It requires hard work and practice - Back To Basics - effective listening is a crucial skill for internal auditors
- FAS 109: a primer for non-accountants - Financial Accounting Standards Board's "Statement 109: Accounting for Income Taxes"
- LIFO vs. FIFO: a return to the basics
- Design a commission plan that drives sales - Sales Commissions
- Too Young to Rent a Car? - 25-years-old the minimum age for car renting - Brief Article
